CADL (Candel Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Candel Therapeutics, Inc. Common Stock (CADL) is a publicly traded Healthcare sector company. As of May 21, 2026, CADL trades at $7.65 with a market cap of $578.83M and a P/E ratio of -10.76. CADL moved +0.78% today. Year to date, CADL is +45.47%; over the trailing twelve months it is +30.46%. Its 52-week range spans $3.79 to $14.60. Analyst consensus is strong buy with an average price target of $21.17. Rallies surfaces CADL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns CADL stock?
Hedge funds tracked by Rallies that own CADL include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Candel Therapeutics, Inc. Common Stock.
CADL Key Metrics
Key financial metrics for CADL
Metric
Value
Price
$7.65
Market Cap
$578.83M
P/E Ratio
-10.76
EPS
$-0.72
Dividend Yield
0.00%
52-Week High
$14.60
52-Week Low
$3.79
Volume
1.32K
Avg Volume
0
Revenue (TTM)
$0
Net Income
$-38.18M
Gross Margin
0.00%
Top Hedge Funds Holding CADL
Exoduspoint Capital holds 227.47K shares of CADL, changed +0.00% as of Mar 31, 2026.
Hedge funds tracked by Rallies that own CADL include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Candel Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for CADL?
Yes. Rallies tracks hedge fund and 13F ownership data for CADL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CADL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CADL. It does not provide personalized investment advice.
